PCI Synthesis

pcisynthesis.com

A Leading Supplier to Life Sciences Companies and Users of Advanced Materials PCI Synthesis is a custom chemical manufacturer of new chemical entities (NCEs), generic APIs, and other specialty chemical products. PCI Synthesis operates two sites in the Greater Boston area.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

Pharmacy Market

FARMACON GLOBAL PARTNERS WITH VALIDCARE FOR PERFORMANCE-BASED CLINICAL RESEARCH SOLUTIONS

Validcare | February 17, 2022

news image

“Validcare’s partnership with Farmacon Global will literally redefine clinical trial success from patient-centric design through database lock,” said Patrick McCarthy CEO Validcare. The Validcare platform accommodates site-based, hybrid and decentralized clinical trials and establishes key performance indicators to ensure study success. “Partnering with Validcare allows our sponsors to quickly identify and implement ROI generating acti...

Read More

OPEN ORPHAN SECURES STUDY TRIAL CONTRACT WITH MYSTERY PHARMACEUTICAL COMPANY

Open Orphan | August 10, 2020

news image

Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial. Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow. The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to ...

Read More

Pharma Tech

INVITAE TO ACQUIRE CIITIZEN TO STRENGTHEN ITS PATIENT-CONSENTED HEALTH DATA PLATFORM TO IMPROVE PERSONAL OUTCOMES AND GLOBAL RESEARCH

Invitae | September 07, 2021

news image

Invitae , a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, whic...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

Pharmacy Market

FARMACON GLOBAL PARTNERS WITH VALIDCARE FOR PERFORMANCE-BASED CLINICAL RESEARCH SOLUTIONS

Validcare | February 17, 2022

“Validcare’s partnership with Farmacon Global will literally redefine clinical trial success from patient-centric design through database lock,” said Patrick McCarthy CEO Validcare. The Validcare platform accommodates site-based, hybrid and decentralized clinical trials and establishes key performance indicators to ensure study success. “Partnering with Validcare allows our sponsors to quickly identify and implement ROI generating acti...

Read More
news image

OPEN ORPHAN SECURES STUDY TRIAL CONTRACT WITH MYSTERY PHARMACEUTICAL COMPANY

Open Orphan | August 10, 2020

Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial. Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow. The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to ...

Read More
news image

Pharma Tech

INVITAE TO ACQUIRE CIITIZEN TO STRENGTHEN ITS PATIENT-CONSENTED HEALTH DATA PLATFORM TO IMPROVE PERSONAL OUTCOMES AND GLOBAL RESEARCH

Invitae | September 07, 2021

Invitae , a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, whic...

Read More